Syndax Pharmaceuticals
SNDX
197 hedge funds and large institutions have $1.79B invested in Syndax Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 88 increasing their positions, 59 reducing their positions, and 18 closing their positions.
170% more call options, than puts
Call options by funds: $6.62M | Put options by funds: $2.46M
49% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 59
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
4% more funds holding
Funds holding: 190 → 197 (+7)
3.47% less ownership
Funds ownership: 106.27% → 102.8% (-3.5%)
24% less capital inflows, than outflows
Capital inflows: $217M | Capital outflows: $287M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avidity Partners Management
Dallas,
Texas
|
+$19.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15M |
| 3 |
First Turn Management
Del Mar,
California
|
+$13.4M |
| 4 |
Prosight Management
Dallas,
Texas
|
+$11.5M |
| 5 |
Sofinnova Investments
Menlo Park,
California
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$45.5M |
| 2 |
BVF Inc
San Francisco,
California
|
-$44.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$25.1M |
| 4 |
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$23.2M |
| 5 |
Morgan Stanley
New York
|
-$22.2M |
SNDX Hedge Fund Activity: Q2 2024 in Review
197 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2024, worth a combined $1.79B — down 17% from $2.15B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new SNDX positions and 18 closed out — a net gain of 8 holders — while 88 added to existing stakes and 59 trimmed.
The largest buyer was Avidity Partners Management, adding an estimated $19.3M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $45.5M.
- 197 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2024, up from 190 in Q1 2024.
- Funds reported $1.79B of Syndax Pharmaceuticals stock for Q2 2024, down 17% quarter-over-quarter.
- 26 funds opened new Syndax Pharmaceuticals positions in Q2 2024 and 18 closed out, a net change of +8 holders.
- The largest Syndax Pharmaceuticals buyer in Q2 2024 was Avidity Partners Management, an estimated $19.3M added.
- The largest Syndax Pharmaceuticals seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $45.5M sold.
Based on aggregated 13F filings for Q2 2024.